Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Clearmind Medicine Inc. - Common Shares
(NQ:
CMND
)
0.1169
-0.0048 (-3.94%)
Streaming Delayed Price
Updated: 10:05 AM EST, Dec 10, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Clearmind Medicine Inc. - Common Shares
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
These stocks are moving in today's after hours session
↗
November 11, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 11, 2025
Via
Benzinga
Top movers analysis one hour before the close of the markets on 2025-11-11: top gainers and losers in today's session.
↗
November 11, 2025
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
Let's take a look at the stocks that are in motion in today's session.
↗
November 11, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
November 11, 2025
Via
Benzinga
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
November 10, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Why Is Clearmind Stock Down Today?
↗
November 07, 2025
Shares of Clearmind Medicine Inc. (NASDAQ: CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 06, 2025
Via
Benzinga
Clearmind Medicine Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
November 06, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Expands Global IP Protection for MEAI in Depression Treatment with New South Korea Patent Filing
November 05, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
These stocks have an unusual volume in today's session
↗
October 31, 2025
In today's session, these stocks are experiencing unusual volume.
Via
Chartmill
Discover the top movers in Friday's pre-market session.
↗
October 31, 2025
Before the US market kicks off on Friday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy
October 31, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
October 30, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine CEO Dr. Adi Zuloff-Shani to Speak at Women in Psychedelic Leadership Webinar
October 28, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact to Advance US Partnerships and Governmental Engagement
October 27, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
October 21, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
October 20, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
October 20, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
September 25, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
September 22, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
September 19, 2025
Via
Benzinga
Which stocks are gapping on Friday?
↗
September 19, 2025
The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via
Chartmill
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
September 19, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
August 28, 2025
Via
Benzinga
SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
August 07, 2025
From
SciSparc Ltd
Via
GlobeNewswire
Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
August 07, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Receives IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center
August 05, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
July 30, 2025
From
Clearmind Medicine Inc.
Via
GlobeNewswire
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
July 30, 2025
From
SciSparc Ltd
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.